Objective: to investigate the importance of various ultrasound prognosis features in the assessment of the cervical ectropion treatment monitoring. Method: The inclusion criteria was the presence of ectropion and the selection was based on clinical examination performed during routine consultations in specialized clinics, later confirmed by colposcopic evaluation of cervix. The evaluation protocol included: clinical evaluation completed with colposcopy, guided biopsy when lesions were suspected, serological assay of day 21 progesteronemy, presence of Chlamydia, Mycoplasma, Ureaplasma, HVS type II, HPV and bacterial infections, transvaginal ultrasound serial evaluation at the 7th, 14th and 21st day before and after tretment concerning: cervical volumetric calculations and velocimetric measurements of uterine arteries flows. Progestative treatment was prescribed, and antiinfectious specific treatment when needed. Patients were reevaluated after 3 months. Results: The prospective study included 45 patients between 2013-2014. 28 presented serum progesterone levels below the reference range or borderline. We noted a moderate reduction of the ectropion area in 42 % and a marked reduction in 58% of the cases. No statistically significant differences were found between the size of the cervix before or after treatment, except certain evaluations (the 7th and the 14th day) in the presence of bacterial coinfections. Evaluation of pulsed Doppler velocimetric indices of uterine arteries flows showed generally minor variations with no constant positive or negative trend. Conclusion: Based on the data obtained in our study, we conclude that ultrasound monitoring of ectropion treatment do not provide reliable prognosis data regarding the evolution of cervical lesion.
Introduction
Cervical cancer worldwide has the third leading incidence of all malignancies in women, ranking in the top five diseases causing mortality [4, 10, 14, 16] . The incidence in Europe is 13.4 per 100,000 women and in our country 34.9 cases per 100,000 women , [5, 6, [38] [39] [40] . Romania has the highest incidence of cancer mortality in the age group 15-44 years in Europe. [34, 35, 37] It is well known that cervical ectropion is a cervical lesion with oncogenic risk, but the studies are still inconsistent on solving this type of injuries [21, 24, 26, 29, 31] . What is more, nowadays the 14-37% reported incidence for cervical ectropion is increasing. [23, 25, 27, 30] Also, aditional diagnosis of Chlamydia, Mycoplasma, Ureaplasma, HPV, HvS2, places the patient into a group of greater oncogenic risk. [1] [2] [3] 8, 13] Antimicrobial-hormonal combined therapy is an important tool to manage such cases with potential dysplastic oncogenic impact [7, 9, 11, 12] . Progesterone administered intermittently during ovulatory to luteal phase, between days 10-14, with varying doses depending on serologically proven deficiency in patients with premenstrual syndrome presenting cervical lesions of the cervix, leads to the induction of transformation zone restriction with re-epithelization in the squamous epithelium [15, 30, 32, 36] . However, there is scarce data in the literature regarding the cervical ultrasound imaging using volumetric, linear and Doppler ultrasound (measurement of uterine artery resistance indices) and prompted our study into this segment. [17, 18, 22, 33] 
Aim
We chose to conduct a sonographic study in patients diagnosed and treated for congenital ectropion to investigate the importance of various ultrasound prognosis features, in order to create an effective algorithm for treatment monitoring.
Methods
During the study period, patients were admitted into the study group after signing an informed consent. Then they were subject to an investigation protocol aimed to investigate the prognosis potential of several measurable cervical parameters that can be used for monitoring the cervical ectropion treatment (Fig.1) .
Inclusion criteria was the presence of ectropion and the selection was based on clinical examination performed during routine consultations in specialized clinics, later confirmed by colposcopic evaluation of cervix.
Demographic data recorded in the patients were: age, origin, characteristics of the menstrual cycle, comorbidities, history of personal or familial cervical pathology. C. Transvaginal ultrasound serial evaluation at the 7th, 14th, 21st day concerning: uterine and cervical volumetric calculations and velocimetric measurements of uterine arteries flows. We used Voluson E6 ultrasound equipment from General Electrics.
After determining the ectropion diagnosis and area, the serologic progesterone level and the infectious context, progestative treatment was prescribed hormone, and antiinfectious specific treatment when needed, with reassessment after 3 months.
Antibiotic protocol was standard with tetracycline, macrolides and quinolones whose efficiency was investigated at 3 months reevaluation. Antiviral therapy was initiated using Isoprinosine for HPV and valacyclovir for HVS2.
Statistical analysis of data For data processing we used IBM SPSS Statistics 20.0 software (IBM Corporation, Armonk, NY, USA).
For data normality tests we used ShapiroWilks and Kolmogorov-Smirnov.
To study the evolution of volumes, IR and ectropion level under therapy, in case of normal distribution of data we used Paired -samples T test and Wilcoxon Signed Rank validity test for data that did not have normal distribution.
Patients were studied as a global group, but also as separate subgroups divided according to different variables.
For data analysis we used frequency tables which included two columns: one for distinct values of the variable analyzed, and the other for frequencies of those values.
Descriptive statistics (mean and standard deviation or median with minimum and maximum value) was used for the presentation of the basic characteristics.
Results
The prospective study included 45 patients between 2013-2014. 
Hormonal profile of patients with ectropion
Patients were divided into 2 subgroups: 28 presented serum progesterone levels below the reference range or borderline reduced and 17 patients had serological values of progesterone in the normal reference interval.
Colposcopic guided biopsy results
Histopathological study with HE staining, of the 45 cases revealed a number of changes in the area of ectropion. Please note that in some cases, were identified two or more microscopic changes described below. Microscopic changes observed with usual staining in ectropion areas were grouped as follows ( 
Systemic and local hormonal treatment
The 50 patients were prescribed with different treatment schedules based on particular benefit for each case. 5 patients were excluded from statistical analysis because they did not accept any hormonal treatment.
In the studied cases semi-synthetic progestogen therapy was indicated in the luteal phase (nomegestrol acetate 5 mg/day or 10-20 mg dydrogesterone/day) or derivatives of natural micronized progesterone.
Colposcopic evaluation after treatment
We noted a moderate reduction of the ectropion area in 19 cases (aproximately 42 % ) and a marked reduction in 26 cases (58%). 
Ultrasonographicstudy results
Cervical volumetry interrelated with menstrual cycle phases (Fig.5 ) No other statistically significant differences were found between the size of the cervix before or after treatment, than differences in absolute value. Cervical volumes were reduced in certain evaluations (for example the 7th and the 14th day) in the presence of bacterial coinfections (Table 3) . After hormonall treatment, followed by the reduction of the ectropion, there were no statistically significant differences in the volumetric measurements of the cervix. (Table 4 ). Cervical volume reduction measured on day 14 of the menstrual cycle, was statistically significant for patients HPV HR+, correlated with low progesterone serologic values. Also, in the same high statistical significance interval, entered patients who experienced frequent menstrual cycles (days 21-25) and in a lesser extent, patients with non specific inflammatory histopathological result. No statistically significant differences were noted in th eoverall cervical volumetric measurement after treatment was administred. However, measurements taken on day 7 and day 21 in patients infected with chlamydia, showed a significant decrease in the cervical volume after treatment and especially after treatment with cephalosporin, but the result should be validated in a larger study. This could suggest a reduction in cervical volume by decreasing inflammation, since hormonal therapy was not significantly involved as an independent variable. The variation of the cervical volume was significant but less notable in the cases of ureaplasma and mycoplasma infections.
Evaluation of uterine artery velocimetry
Evaluation of pulsed Doppler velocimetric indices of uterine arteries flows showed absolute variations but the vast majority were minor, up to 25% from the initial findings. We could not identify a constant positive or negative trend, in any of the uterine arteries, during the menstrual cycle, and also the indices varied widely as amplitude. Note that these indexes have suffered the most significant changes in the periovulatory phase at the left uterine artery towards lower values, but later in the day 21, in the end of treatment, the respective indices were increased compared to previous values. Moreover, this trend has not been followed by the measurements in the contralateral uterine artery. Since changes were inconstant and minor, we conclude that uterine vasculature was not influenced by the treatment or remission of the cervical ectropion . An issue that requires further investigation with possible prognostic implication is that the changes in resistance uterine arteries index was higher in patients without Chlamydia infection and positive for HPV-HR infection and patients with low progesteronemy. It might be true the hypotesys that progesterone therapy is more effective if the ectropion is "clean" bacteriological and viral, but this assumption requires confirmation by further research with similar therapeutic protocol. Based on the data obtained in our study, we conclude that ultrasound monitoring of ectropion treatment do not provide reliable prognosis data regarding the evolution of cervical lesion. 
